Abstracts Archive - Page 215 of 2607 - ACR Meeting Abstracts

Abstract Number: 0522 • ACR Convergence 2024
Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment
Soo Min Ahn, Mi-Ra Cho, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors' introduction has significantly revolutionized the therapeutic landscape, notably influencing the management strategies for rheumatoid arthritis (RA). To compare the effects…
Abstract Number: 0565 • ACR Convergence 2024
Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
Anthony Lichaa¹, Pauline KRUG¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
Abstract Number: 0575 • ACR Convergence 2024
Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA
Kurt de Vlam¹, Pieter Ruytinx², Elien luyten², Anouk Agten², Frank Vandenabeele² and Veerle somers², ¹Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ²Universiteit Hasselt, Hasselt, Belgium
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
Abstract Number: 0577 • ACR Convergence 2024
AMH Titers in Women with Axial Spondyloarthritis Are Significantly Lower Compared to the General Population: An Analysis of the 10-year Follow-up of the DESIR Cohort
Madeleine FRANC¹, Jean Guibourdenche², Anne Tournadre³ and Anna Molto⁴, ¹Groupe Hospitalier Cochin, APHP, Paris, France, ²Groupe Hospitalier Cochin, APHP, Paris, ³Service de Rhumatologie, centre hospitalier universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France, ⁴Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Data on fertility in women with spondyloarthritis (SpA) is sparse but seems to be impaired compared to the general population. Divergent results have been…
Abstract Number: 0581 • ACR Convergence 2024
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with reduced radiographic progression and improved quality of life among patients (pts) with PsA.1 Clinical advances made MDA…
Abstract Number: 0560 • ACR Convergence 2024
Association Between a Self-Report Screening Tool for Sarcopenia (SARC-F) and Disease Activity, Muscle Strength and Muscle Power Measures, Patient-Reported Outcomes and Body Composition in Patients with Spondyloarthritides
Iuliia Kononenko¹, Marius Bedei², Bjoern Buehring³, Xenofon Baraliakos⁴ and Uta Kiltz⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Bochum, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Herne, Germany, ³Bergisches Rheuma-Zentrum, Wuppertal, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany
Background/Purpose: The SARC-F is a self-report screening tool for sarcopenia (Sar) used to identify individuals at risk for poor functional outcomes [1]. The aim of this study was…
Abstract Number: 0579 • ACR Convergence 2024
Association of the Presence of Active Acute Anterior Uveitis with Disease Activity in Axial Spondyloarthritis
Judith Rademacher¹, Murat Torgutalp², Lynn zur Bonsen¹, Dominika Pohlmann¹, Hildrun Haibel¹, Fabian Proft¹, Mikhail Protopopov³, Uwe Pleyer¹, Valeria Rios Rodriguez¹ and Denis Poddubnyy⁴, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charite Universitatsmedizin - Berlin, Berlin, Germany, ³Charite – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charite-Universitatsmedizin Berlin, Berlin, Germany
Background/Purpose: Acute anterior uveitis (AAU) and axial spondyloarthritis (axSpA) are closely linked, with AAU being the most common extra-musculoskeletal manifestation of axSpA. Up to half…
Abstract Number: 0533 • ACR Convergence 2024
Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial
Maike Wientjes¹, Sadaf Atiqi², Gertjan Wolbink³, Michael Nurmohamed⁴, Maarten Boers⁵, Femke Hooijberg², Theo Rispens⁶, Annick De Vries⁶, Floris Loeff⁶, Ronald Van Vollenhoven⁷, Sofia Ramiro⁸, Noortje van Herwaarden⁹, Bart van den Bemt¹⁰ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Reade, Amsterdam, Netherlands, ³Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Reade and Amsterdam UMC, Kortenhoef, Netherlands, ⁵Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁶Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands, ⁹Sint Maartenskliniek, Nijmegen, Netherlands, ¹⁰Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Adalimumab is an effective and safe treatment for RA, however a substantial proportion of RA patients discontinue its use due to inefficacy. Upon failure,…
Abstract Number: 2461 • ACR Convergence 2024
Prevalence and Impact of Peripheral Neuropathy in SSc: A Frequent and Disabling Manifestation in SSc, and a Potential Surrogate Marker for Autonomic Neuropathy
Begonya Alcacer-Pitarch¹, marco di battista², Anthony C. Redmond³, Anne-Maree Keenan⁴, Stefano Di Donato⁵, Francesco Del Galdo³ and Maya H. Buch⁶, ¹Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Rheumatology Unit, University of Pisa, Pisa., Pisa., Italy, ³University of Leeds, Leeds, United Kingdom, ⁴School of Healthcare, university of leeds, leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁶Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: SSc patients have high disability and low quality of life (QoL), driven partially by poor physical function (PF), Gastro Intestinal (GI) problems, digital ulcers…
Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Ismael Gonzalez⁴, Ignacio Gonzalez Fernandez⁵, Carolina Díez Morrondo⁵, Carolina Alvarez Castro⁶, Paula Perez Garcia⁵, Jose Ordas Martínez⁵, Pedro Baenas Gonzalez⁵ and elvira Diez álvarez⁵, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, León, Spain, ⁵Complejo Asistencial Universitario de Leon, Leon, ⁶Complejo Asistencial Universitario de Leon, Leon, Spain
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…
Abstract Number: 0499 • ACR Convergence 2024
PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
Wanki Ho¹, Huaqun Zhu¹, Hua Ye¹, Dongdong Fu² and Xi Xu¹, ¹Peking University People's Hospital, Beijing, China, ²Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)
Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
Abstract Number: 2464 • ACR Convergence 2024
Thymic Size Longitudinal Changes on Chest High-resolution Computed Tomography After Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis
Grégory Pugnet¹, Samia Collot², Antoine Petermann³, Pauline Lansiaux⁴, Gwenaelle Larion⁴, Mathieu Resche-rigon⁴, Cécile Borel⁵, Zora Marjanovic⁶ and Dominique Farge⁴, ¹Toulouse Rangueil University Hospital, Toulouse, France, ²CHU Toulouse, Toulouse, France, ³Clinique Pasteur, Toulouse, France, ⁴APHP, PAris, France, ⁵IUCT, Toulouse, France, ⁶APHP, Toulouse, France
Background/Purpose: The thymus is a central lymphatic organ responsible for T-cell differentiation and maturation throughout life. The thymus reaches its maximum absolute weight at puberty,…
Abstract Number: 0544 • ACR Convergence 2024
A Two-year Comparison of Spinal and Hip Mobility Between Axial Spondyloarthritis and Chronic Back Pain Patients in the SPondyloArthritis Caught Early (SPACE) Cohort
Ana Bento da Silva¹, Sofia Ramiro², Miranda van Lunteren¹, Mary Lucy Marques³, Marleen Van De Sande⁴, Camilla Fongen⁵, Sofia Exarchou⁶, Roberta Ramonda⁷, Desiree van der Heijde⁸ and Floris van Gaalen⁹, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Bunde, Netherlands, ³Leiden University Medical Center, Coimbra, Zuid-Holland, Portugal, ⁴Amsterdam Institute for Infection & Immunity and Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Lund University, Åkarp, Sweden, ⁷Rheumatology Unit, University of Padova, Italy, Padova, Italy, ⁸Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁹LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) frequently leads to reduced spinal and hip mobility, though evidence pertains mostly to patients with longstanding disease and radiographic damage. More…
Abstract Number: 2480 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
Robert Spiera¹, Robert Lebovics², Sarah Bray³, Rachel E. Gurlin⁴, David Jayne⁵ and Peter Merkel⁶, and ADVOCATE Study Group, ¹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²Hackensack Meridian University Health System, Hackensack, NJ, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].